We are live on ! Find out more
EAM

Erste Asset Management Portfolio holdings

AUM $12.9B
1-Year Est. Return 52.69%
This Fund
S&P 500
This Quarter Est. Return
+7.94%
1 Year Est. Return
+52.69%
3 Year Est. Return
+142.55%
5 Year Est. Return
+182.36%
10 Year Est. Return
AUM
$4.09B
AUM Growth
+$472M
Cap. Flow
+$292M
Cap. Flow %
7.14%
Top 10 Hldgs %
16.99%
Holding
524
New
29
Increased
201
Reduced
78
Closed
20

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$24.1M
2
NVDA icon
NVIDIA
NVDA
+$16.3M
3
AMAT icon
Applied Materials
AMAT
+$16.2M
4
PH icon
Parker-Hannifin
PH
+$15.5M
5
VSAT icon
Viasat
VSAT
+$15M

Top Sells

Rank Stock Value
1
ON icon
ON Semiconductor
ON
+$42.2M
2
TPR icon
Tapestry
TPR
+$11.6M
3
BLK icon
Blackrock
BLK
+$11.2M
4
ICE icon
Intercontinental Exchange
ICE
+$10.8M
5
PLUG icon
Plug Power
PLUG
+$10.5M

Sector Composition

Rank Sector Weight
1 Technology 27.85%
2 Healthcare 19.52%
3 Consumer Discretionary 15.8%
4 Industrials 10.21%
5 Financials 8.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTLA icon
351
Intellia Therapeutics
NTLA
$1.63B
$708K 0.02%
9,800
-7,800
-44% -$524K
STLD icon
352
Steel Dynamics
STLD
$34.8B
$703K 0.02%
13,700
FMC icon
353
FMC
FMC
$1.39B
$701K 0.02%
6,339
+2,485
+64% +$275K
SLB icon
354
SLB Ltd
SLB
$79.5B
$700K 0.02%
25,700
-25,700
-50% -$677K
ITCI
355
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$683K 0.02%
21,000
KALA icon
356
KALA BIO
KALA
$10.3M
$672K 0.02%
42
AVY icon
357
Avery Dennison
AVY
$13.1B
$667K 0.02%
3,600
AUTL
358
Autolus Therapeutics
AUTL
$514M
$659K 0.02%
+120,000
New +$888K
KO icon
359
Coca-Cola
KO
$380B
$659K 0.02%
12,434
PBA icon
360
Pembina Pipeline
PBA
$27.6B
$643K 0.02%
22,400
+3,000
+15% +$83.4K
LGND icon
361
Ligand Pharmaceuticals
LGND
$5.52B
$641K 0.02%
6,893
AJG icon
362
Arthur J. Gallagher & Co
AJG
$62.7B
$641K 0.02%
5,100
QIWI
363
DELISTED
QIWI PLC
QIWI
$639K 0.02%
60,000
ARVN icon
364
Arvinas
ARVN
$540M
$638K 0.02%
10,200
BTG icon
365
B2Gold
BTG
$6.99B
$632K 0.02%
146,758
+70,129
+92% +$342K
ALXO icon
366
ALX Oncology
ALXO
$264M
$629K 0.02%
9,200
FFIV icon
367
F5
FFIV
$24.5B
$623K 0.02%
3,000
FCX icon
368
Freeport-McMoran
FCX
$99.9B
$622K 0.02%
19,000
TRP icon
369
TC Energy
TRP
$63.7B
$609K 0.01%
13,100
EWA icon
370
iShares MSCI Australia ETF
EWA
$1.27B
$583K 0.01%
+23,500
New +$585K
KMI icon
371
Kinder Morgan
KMI
$68.2B
$565K 0.01%
34,000
-16,000
-32% -$244K
MGNX icon
372
MacroGenics
MGNX
$261M
$560K 0.01%
18,000
TWST icon
373
Twist Bioscience
TWST
$9.71B
$549K 0.01%
5,000
-6,900
-58% -$1.05M
MCRB icon
374
Seres Therapeutics
MCRB
$46M
$525K 0.01%
1,350
ON icon
375
ON Semiconductor
ON
$28.4B
$518K 0.01%
12,460
-1,100,000
-99% -$42.2M

Similar funds

Erste Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Erste Asset Management held 524 positions worth $4.09B, up 13% from $3.61B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Erste Asset Management deployed $292M of net new capital in Q1 2021, opening 29 new positions and adding to 201 existing holdings. Its largest new stake was Parker-Hannifin: 53,700 shares worth $17M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was ON Semiconductor, an estimated $42.2M trimmed.

  • Erste Asset Management's largest Q1 2021 buy was Parker-Hannifin: 53,700 shares worth $17M.
  • Erste Asset Management added most to Sarepta Therapeutics in Q1 2021, an estimated $24.1M increase.
  • Erste Asset Management's biggest Q1 2021 reduction was ON Semiconductor, cutting an estimated $42.2M.
  • Erste Asset Management fully exited Workhorse Group in Q1 2021, selling an estimated $7.32M.
  • Erste Asset Management's ten largest holdings make up 17% of its $4.09B portfolio in Q1 2021.
  • Erste Asset Management opened 29 new positions and closed 20 in Q1 2021.
  • Erste Asset Management's portfolio value rose 13% quarter-over-quarter to $4.09B.

Based on Erste Asset Management's 13F filing for Q1 2021, filed 25 Nov 2024.